Skip to Main content Skip to Navigation
New interface

Rôle et régulation de la phosphodiestérase de type 2 dans l’insuffisance cardiaque

Abstract : Cyclic AMP (cAMP) and cyclic GMP (cGMP) are critical second messengers for the regulation of cardiac function. Their levels are regulated by adenylyl and guanylyl cyclases, respectively, and by cyclic nucleotides phosphodiesterases (PDEs). However, such regulation is altered in heart failure (HF). Indeed diminished cAMP- and augmented cGMP-signaling is characteristic of failing hearts.Among the PDE superfamily, PDE2 has the unique property to be stimulated by cGMP, thus leading to a remarkable increase in cAMP hydrolysis. This appears to mediate a negative cross-talk between cAMP- and cGMP signaling pathways. However, the role of PDE2 in the failing heart is only poorly understood.In this context, we investigated whether myocardial PDE2 is altered in human and experimental HF and determined PDE2 mediated effects on β-adrenoceptor (β-AR) signaling in cardiomyocytes. Using immunoblotting, radioenzymatic- and FRET-based assays, video-edge-detection, epifluorescent microscopy and L-type Ca2+ current measurements, performed in myocardial tissues and/or isolated cardiomyocytes from human and/or experimental HF, respectively, we showed that PDE2 is markedly upregulated in failing hearts. This reduces the effect of an acute β-adrenergic stimulation, and contributes to the β-adrenergic desensitization which is a characteristic feature in HF. Accordingly, PDE2 overexpression in healthy cardiomyocytes reduced the rise in cAMP levels and ICa,L amplitude and abolished the inotropic effect following acute β-AR stimulation, without affecting basal contractility. Importantly, PDE2-overexpressing cardiomyocytes showed marked protection from norepinephrine-induced hypertrophic responses and from isoproterenol-induced arrhythmias.In conclusion, this work highlights the alteration of PDE2 in HF and lets us assume that PDE2 upregulation in HF may constitute an important defence mechanism during cardiac stress, e.g. by antagonizing excessive β-AR drive. Thus, activating myocardial PDE2 may represent a novel intracellular anti-adrenergic therapeutic strategy in HF.
Document type :
Complete list of metadata
Contributor : ABES STAR :  Contact
Submitted on : Monday, June 2, 2014 - 1:06:50 AM
Last modification on : Tuesday, October 18, 2022 - 3:41:05 AM
Long-term archiving on: : Tuesday, April 11, 2017 - 2:26:15 AM


Version validated by the jury (STAR)


  • HAL Id : tel-00998374, version 1



Hind Mehel. Rôle et régulation de la phosphodiestérase de type 2 dans l’insuffisance cardiaque. Sciences agricoles. Université Paris Sud - Paris XI, 2013. Français. ⟨NNT : 2013PA114831⟩. ⟨tel-00998374⟩



Record views


Files downloads